Zentalis Pharmaceuticals, Inc. Shares Rise After Trial Data Release

Your call?🐂 Bullish🐻 Bearish

15.8 months

median overall survival

Median overall survival was 15.8 months for 48 patients whose tumors tested positive for Cyclin E1, versus 7.5 months for 46 who tested negative.